DK1025209T3 - Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine - Google Patents

Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine

Info

Publication number
DK1025209T3
DK1025209T3 DK98941885T DK98941885T DK1025209T3 DK 1025209 T3 DK1025209 T3 DK 1025209T3 DK 98941885 T DK98941885 T DK 98941885T DK 98941885 T DK98941885 T DK 98941885T DK 1025209 T3 DK1025209 T3 DK 1025209T3
Authority
DK
Denmark
Prior art keywords
japanese encephalitis
vero cell
attenuated
vaccine
virus adapted
Prior art date
Application number
DK98941885T
Other languages
Danish (da)
English (en)
Inventor
Hyun Su Kim
Wang Don Yoo
Soo Ok Kim
Sung Hee Lee
Sang Bum Moon
Sun Pyo Hong
Yong Cheol Shin
Yong Ju Chung
Kenneth H Eckels
Bruce Innis
Joseph R Putnak
Leonard N Binn
Ashok K Srivastava
Doria R Dubois
Original Assignee
Cheil Jedang Corp
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheil Jedang Corp, Us Army filed Critical Cheil Jedang Corp
Application granted granted Critical
Publication of DK1025209T3 publication Critical patent/DK1025209T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98941885T 1997-08-28 1998-08-25 Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine DK1025209T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042001 1997-08-28
KR19970042002 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (1)

Publication Number Publication Date
DK1025209T3 true DK1025209T3 (da) 2007-06-25

Family

ID=26633032

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98941885T DK1025209T3 (da) 1997-08-28 1998-08-25 Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine
DK05014317.1T DK1604685T3 (da) 1997-08-28 1998-08-25 Et svækket japansk encephalitisvirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05014317.1T DK1604685T3 (da) 1997-08-28 1998-08-25 Et svækket japansk encephalitisvirus

Country Status (15)

Country Link
US (1) US6309650B1 (enExample)
EP (2) EP1604685B1 (enExample)
JP (1) JP4161017B2 (enExample)
KR (1) KR100314404B1 (enExample)
CN (1) CN1142271C (enExample)
AU (1) AU748730B2 (enExample)
CA (1) CA2301000C (enExample)
DE (2) DE69837211T2 (enExample)
DK (2) DK1025209T3 (enExample)
ES (2) ES2382946T3 (enExample)
FR (1) FR09C0037I2 (enExample)
MY (1) MY129773A (enExample)
NL (1) NL300391I2 (enExample)
NZ (1) NZ503522A (enExample)
WO (1) WO1999011762A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
KR20010032699A (ko) * 1998-10-05 2001-04-25 무따이 마사히꼬 일본 뇌염 바이러스 감염에 대한 불활성 백신을 위한증강된 면역원 및 그 제조방법
ES2348159T3 (es) * 1999-04-22 2010-11-30 United States Department Of Agriculture Vacuna contra el sindrome respiratorio y reproductivo porcino basada en el aislado ja-142.
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
JP2004531578A (ja) * 2001-06-29 2004-10-14 ベクトン・ディキンソン・アンド・カンパニー ワクチンおよび遺伝子治療剤のマイクロカニューレによる皮内送達
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
ES2329607T3 (es) * 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
US8574595B2 (en) * 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
EP2117589A4 (en) * 2007-01-31 2010-07-21 Sanofi Pasteur Biologics Co FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
MY173418A (en) * 2007-12-26 2020-01-23 Daiichi Sankyo Co Ltd Method of producing japanese encephalitis avccines stably storable over long time and use of the vaccine
JP5511660B2 (ja) * 2008-06-04 2014-06-04 一般財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
KR101622738B1 (ko) * 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
RS56709B1 (sr) 2011-12-06 2018-03-30 Valneva Austria Gmbh Jedinjenja aluminijuma za primenu u terapeuticima i vakcinama
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2015059714A1 (en) * 2013-09-14 2015-04-30 Bharat Biotech International Limited Emergency mode in a hybrid vehicle
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
EP4357355A3 (en) 2015-12-23 2024-09-25 Valneva SE Virus purification
WO2017122635A1 (ja) * 2016-01-15 2017-07-20 一般財団法人化学及血清療法研究所 固定化ウイルス粒子を含むワクチン
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
KR102757369B1 (ko) 2017-09-21 2025-01-20 발네바 에스이 면역원성 치쿤구니야 바이러스 chikv-델타5nsp3을 포함하는 약제학적 조성물의 생산 방법
CA3081586A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN116983398A (zh) 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
CN110684747B (zh) 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
US20210277361A1 (en) * 2018-08-27 2021-09-09 Mican Technologies Inc. Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
IL296071A (en) 2020-03-01 2022-11-01 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
US12605442B2 (en) 2020-03-06 2026-04-21 Colorado State University Research Foundation Production of vaccines comprising inactivated SARS-CoV-2 viral particles
UY39159A (es) 2020-04-06 2021-10-29 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4428231A4 (en) * 2022-04-20 2025-11-19 Korea Nat Institute Of Health GENOTYPE 5 OF HIGH-TIRES JAPANESE ENCEPHALITIS VIRUS AND ITS USE
WO2024153686A1 (en) 2023-01-18 2024-07-25 Valneva Austria Gmbh Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
EP1604685A3 (en) 2006-07-05
NZ503522A (en) 2001-06-29
KR19990023955A (ko) 1999-03-25
WO1999011762A1 (en) 1999-03-11
DE69837211D1 (de) 2007-04-12
ES2281929T3 (es) 2007-10-01
KR100314404B1 (ko) 2002-10-12
DE122009000037I2 (de) 2011-06-16
AU748730B2 (en) 2002-06-13
DE69837211T2 (de) 2007-12-06
DE122009000037I1 (de) 2009-11-05
EP1604685B1 (en) 2012-02-22
CN1272879A (zh) 2000-11-08
EP1604685A2 (en) 2005-12-14
EP1025209A1 (en) 2000-08-09
AU9004798A (en) 1999-03-22
EP1025209B1 (en) 2007-02-28
ES2382946T3 (es) 2012-06-14
MY129773A (en) 2007-04-30
US6309650B1 (en) 2001-10-30
NL300391I2 (nl) 2009-11-02
DK1604685T3 (da) 2012-06-18
JP4161017B2 (ja) 2008-10-08
CN1142271C (zh) 2004-03-17
FR09C0037I1 (enExample) 2009-09-25
FR09C0037I2 (fr) 2021-11-05
NL300391I1 (nl) 2009-08-03
CA2301000A1 (en) 1999-03-11
CA2301000C (en) 2003-07-08
JP2001514844A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
NL300391I1 (nl) Een verzwakt Japanse encefalitis-virus aangepast aan Vero-cellen en een Japanse encefalitis-vaccin
NO20004104L (no) Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater
DE69517206D1 (de) Virenschutz in rechnersystemen
DK0810877T3 (da) Hepatitis B-vaccine
FI942369L (fi) Hepatitis-C-virustesti
DE69504868D1 (de) Gasextraktionsvorrichtung
EP1037974A4 (en) TRUNCATED PROTEIN OF HEPATITIS C VIRUS NS5B AND RELATED METHODS OF IDENTIFYING ANTIVIRAL COMPOUNDS
DK1310167T3 (da) Forbedret celleudformning til et trawlsystem og fremgangsmåder
DK1228193T3 (da) Felint calicivirirus-gener og rekombinante vacciner der indeholder dem
NO971495L (no) Svekkede virus og fremgangsmåte til deres fremstilling
BR9403166A (pt) Catalisador de gás de escape
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
ATE277631T1 (de) Neospora impstoff
DE69803598D1 (de) Nachweisverfahren und -vorrichtung
FI922732A0 (fi) Ljudisolerad faeste foer en ultra- ljudomformare.
DE68908592D1 (de) Abgasrekombinator.
NO976052D0 (no) Fremgangsmåte og system for seriefeilvern
BR8902852A (pt) Sistema de recuperacao de metal precioso e aparelho de recuperacao de mercurio
KR980004483U (ko) 가스와 연막을 이용한 방범장치
FI922902A7 (fi) Kaasun ilmaisujärjestelmä
FI972091L (fi) Menetelmä ja järjestely prosessorin liittämiseksi ASIC-piiriin
DE69824881D1 (de) Kompakte replikons des epstein-barr-virus.
KR950015526U (ko) 배기카트 안전망 감지장치
KR950018692U (ko) 배기 기능을 갖는 깔때기
SE9202575D0 (sv) Turbinbladsskydd (gasturbin)